288. Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details


Clinical trials : 205 Drugs : 238 - (DrugBank : 31) / Drug target genes : 18 - Drug target pathways : 26

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-003036-37-AT
(EUCTR)
27/10/201714/09/2017The influence of the medication Willfact on the blood loss of patient during the use of a heart-lung machineA double-blind, placebo-controlled pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenation - Von Willebrand factor concentrate during ECMO support Von Willebrand Disease (VWD)
MedDRA version: 20.0;Level: PT;Classification code 10069495;Term: Acquired Von Willebrand's disease;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Willfact
Product Name: Willfact
INN or Proposed INN: von Willebrand Faktor
Other descriptive name: VON WILLEBRAND FACTOR
Trade Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung
Product Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung
INN or Proposed INN: Natriumchlorid 0,9 %
Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%
Trade Name: Willfact
Product Name: Willfact
INN or Proposed INN: von Willebrand Faktor
Other descriptive name: VON WILLEBRAND FACTOR
Trade Name: Willfact
Product Name: Willfact
INN or Proposed INN: von Willebrand Faktor
Other descriptive name: VON WILLEBRAND FACTOR
Tirol Kliniken GmbHNULLNot RecruitingFemale: yes
Male: yes
68Phase 2Austria
2EUCTR2016-000789-53-AT
(EUCTR)
09/03/201717/10/2016The influence of the medication Willfact on the blood loss of patient during the use of a heart-lung machineA pilot trial to investigate the administration of von Willebrand factor concentrate (Willfact®, LFB France) in adult patients during extracorporeal membrane oxygenation - Willfact during ECMO Von Willebrand Disease (VWD)
MedDRA version: 19.1;Level: PT;Classification code 10069495;Term: Acquired Von Willebrand's disease;System Organ Class: 10005329 - Blood and lymphatic system disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Willfact
Product Name: Willfact
INN or Proposed INN: von Willebrand Faktor
Other descriptive name: VON WILLEBRAND FACTOR
Trade Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung
Product Name: Physiologische Kochsalzlösung Fresenius - Infusionslösung
INN or Proposed INN: Natriumchlorid 0,9 %
Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%
Trade Name: Willfact
Product Name: Willfact
INN or Proposed INN: von Willebrand Faktor
Other descriptive name: VON WILLEBRAND FACTOR
Trade Name: Willfact
Product Name: Willfact
INN or Proposed INN: von Willebrand Faktor
Other descriptive name: VON WILLEBRAND FACTOR
Medizinische Universität Innsbruck / Univ.-Klinik für Allgemeine und Chirurgische IntensivmedizinNULLNot RecruitingFemale: yes
Male: yes
Phase 2Austria